Skip to main content
Elanix Biotechnologies AG logo

Elanix Biotechnologies AG — Investor Relations & Filings

Ticker · ELN ISIN · DE000A0WMJQ4 LEI · 391200SYNFFL0NPAJK90 F Manufacturing
Open in API
Filings indexed 161 across all filing types
Latest filing 2017-01-13 Share Issue/Capital Cha…
Country DE Germany
Listing F ELN

About Elanix Biotechnologies AG

https://elanixbiotechnologies.com/

Elanix Biotechnologies AG is a tissue regeneration company that develops and commercializes products for acute wound care, dermatological, and gynecological applications. The company's core focus is on creating therapeutic solutions derived from progenitor cells. Its product development pipeline aims to provide advanced treatments for skin and tissue repair.

Recent filings

Filing Released Lang Actions
Elanix Biotechnologies AG: CEO informs about planned cash capital increase with indirect subscription rights
Share Issue/Capital Change Classification · 99% confidence The document is an 'Ad-hoc' announcement dated January 13, 2017, explicitly stating that the CEO informs about a 'planned cash capital increase with indirect subscription rights'. The text discusses the intent to resolve on a capital increase later this month using existing Authorised Capital. This directly relates to changes in the company's capital structure and fundraising activities. Based on the definitions, 'Capital/Financing Update' (CAP) is the most appropriate classification for an announcement detailing a planned capital increase.
2017-01-13 English
Elanix Biotechnologies AG announces non-binding letter of intent with Oxford MEStar Ltd. in regard to setting up a JV to market GynRepair in China
M&A Activity Classification · 99% confidence The document is a press release announcing that Elanix Biotechnologies AG has entered into a non-binding letter of intent (LOI) with Oxford MEStar Ltd. regarding a potential joint venture to market a product in China. The key phrase is 'announces non-binding letter of intent (LOI)'. This type of announcement, detailing strategic business development or partnership intentions that are not yet definitive agreements, typically falls under general corporate news or regulatory filings. Since there is no specific category for 'Letter of Intent' or 'Strategic Partnership Announcement', and it is not a formal financial report (10-K, IR, ER), nor a management change (MANG) or dividend notice (DIV), it is best classified as a general Regulatory Filing (RNS) as per the definition: 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories.' The document length is substantial (6335 chars), so it is not an RPA.
2016-11-22 English
Elanix Biotechnologies AG: ELANIX BIOTECHNOLOGIES AG STRATEGIC PARTNER, TRANSWELL BIOTECHNOLOGY LTD., RECEIVES US FDA CLEARANCE FOR PHASE I/II CLINICAL TRIAL USING FIBROBLAST PROGENITORS TWB-103
Regulatory Filings Classification · 95% confidence The document is a news release dated November 8, 2016, disseminated via DGAP-News. It announces that Elanix Biotechnologies AG's strategic partner received US FDA clearance for a Phase I/II clinical trial. The content focuses on a specific corporate development (FDA clearance for a clinical trial) rather than comprehensive financial reporting (like 10-K or IR) or a general announcement of a report's release (RPA). Since it is a specific, material corporate announcement that doesn't fit the other specialized categories (like DIRS, DIV, MANG, etc.), it falls best under the general regulatory announcement category, RNS, which serves as a fallback for material news releases not covered elsewhere. The length (8686 chars) suggests it is the full content, not just a short announcement of a report.
2016-11-08 English
ELANIX BIOTECHNOLOGIES AG, KEY PATENT FOR THE PREPARATION OF PARENTAL CELL BANK GRANTED IN THE U.S.A.
Regulatory Filings Classification · 95% confidence The document is a news release disseminated via DGAP, announcing that Elanix Biotechnologies AG has been granted a key patent (U.S. Patent No. 9434923 B2) for the preparation of a parental cell bank. This is a specific corporate event announcement related to intellectual property and business development, not a standard periodic financial report (like 10-K or IR), a management discussion (MDA), or an earnings release (ER). Since there is no specific category for 'Patent Grant Announcement,' and it is a general corporate news item transmitted through a regulatory distribution service (DGAP), the most appropriate fallback category is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit elsewhere.
2016-10-25 English
ELANIX BIOTECHNOLOGIES AG subsidiary acquires 100% of equity of Repair-A SA
M&A Activity Classification · 100% confidence The document is an 'Ad-hoc' disclosure dated September 30, 2016, announcing that a subsidiary of Elanix Biotechnologies AG acquired 100% of the equity of Repair-A SA. The key phrase indicating the nature of the event is 'Key word(s): Takeover' and the content details a corporate acquisition/merger activity. This directly aligns with the definition for M&A Activity (TAR). Although it is an announcement, it is the primary disclosure of the transaction itself, not merely an announcement about the publication of a report (RPA) or a general regulatory filing (RNS).
2016-09-30 English
Report Publication Announcement 2016
Report Publication Announcement Classification · 100% confidence The document is a very short announcement (1630 chars) dated September 27, 2016, titled 'Preliminary announcement of the publication of financial reports'. It explicitly states that the 'Financial report of the group (half-year/Q2)' will be disclosed on September 29, 2016, and provides links to where the report will be available. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report is being published or attached classifies as a Report Publication Announcement (RPA), not the report itself (which would be an IR or 10-K).
2016-09-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.